MAI Capital Management’s MaxCyte MXCT Stock Holding History

MAI Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-242	Closed	-$170	–	3725
2026 Q1	$170	Buy	+242	New	+$226	﹤0.01%	4654

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

MAI Capital Management's MXCT Position: Q2 2026 in Review

MAI Capital Management sold out of MaxCyte (MXCT) in Q2 2026, closing a stake of 242 shares — an estimated $170 sold.

MAI Capital Management first reported a position in MXCT in Q1 2026 and held it in 1 quarter. The position peaked at $170 in Q1 2026. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

MAI Capital Management reported no remaining MaxCyte position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 242 MaxCyte shares in Q2 2026, an estimated $170.
MAI Capital Management first reported a position in MaxCyte in Q1 2026 and held it in 1 quarter.
MAI Capital Management's MaxCyte position peaked at $170 in Q1 2026.
122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.